170 related articles for article (PubMed ID: 36374561)
21. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
22. Exosomes loaded with programmed death ligand-1 promote tumor growth by immunosuppression in osteosarcoma.
Zhang L; Xue L; Wu Y; Wu Q; Ren H; Song X
Bioengineered; 2021 Dec; 12(2):9520-9530. PubMed ID: 34699324
[TBL] [Abstract][Full Text] [Related]
23. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
Ye L; Zhu Z; Chen X; Zhang H; Huang J; Gu S; Zhao X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831468
[TBL] [Abstract][Full Text] [Related]
24. Single-Step and Highly Sensitive Imaging of Exosomal PD-L1 through Aptamer-Activated Cascade Primer Exchange Reaction-Generated Branched DNA Nanostructures.
Li X; Li X; Cheng X; Bian X; Shen B; Ding X; Ding S
ACS Sens; 2022 Nov; 7(11):3571-3579. PubMed ID: 36329604
[TBL] [Abstract][Full Text] [Related]
25. High Throughput and Noninvasive Exosomal PD-L1 Detection for Accurate Immunotherapy Response Prediction via Tim4-Functionalized Magnetic Core-Shell Metal-Organic Frameworks.
Wang H; Liu Y; Zhang L; Li X; Zhao G; Song Z; Jia Y; Qiao X
Anal Chem; 2023 Dec; 95(49):18268-18277. PubMed ID: 38011622
[TBL] [Abstract][Full Text] [Related]
26. The Detection of Exosomal PD-L1 in Peripheral Blood.
Wang R; Yang Y; Huang J; Yao Y
Methods Mol Biol; 2023; 2695():195-212. PubMed ID: 37450120
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
[TBL] [Abstract][Full Text] [Related]
28. Personalized detection of circling exosomal PD-L1 based on Fe
Pang Y; Shi J; Yang X; Wang C; Sun Z; Xiao R
Biosens Bioelectron; 2020 Jan; 148():111800. PubMed ID: 31678824
[TBL] [Abstract][Full Text] [Related]
29. [Expression and significance of programmed cell death ligand-1 in neuroblastoma tissues].
Liao R; Sun XF; Zhen ZZ; Huang DS
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):735-740. PubMed ID: 30293276
[No Abstract] [Full Text] [Related]
30. The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer.
Tang Y; Zhang P; Wang Y; Wang J; Su M; Wang Y; Zhou L; Zhou J; Xiong W; Zeng Z; Zhou Y; Nie S; Liao Q
Front Immunol; 2020; 11():604. PubMed ID: 32322256
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
32. Nanoplasmonic Sandwich Immunoassay for Tumor-Derived Exosome Detection and Exosomal PD-L1 Profiling.
Wang C; Huang CH; Gao Z; Shen J; He J; MacLachlan A; Ma C; Chang Y; Yang W; Cai Y; Lou Y; Dai S; Chen W; Li F; Chen P
ACS Sens; 2021 Sep; 6(9):3308-3319. PubMed ID: 34494426
[TBL] [Abstract][Full Text] [Related]
33. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract][Full Text] [Related]
34. LINC00657 activates PD-L1 to promote osteosarcoma metastasis via miR-106a.
Zhang J; Chou X; Zhuang M; Zhu C; Hu Y; Cheng D; Liu Z
J Cell Biochem; 2020 Oct; 121(10):4188-4195. PubMed ID: 31898338
[TBL] [Abstract][Full Text] [Related]
35. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
[TBL] [Abstract][Full Text] [Related]
37. A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.
Del Re M; Cucchiara F; Rofi E; Fontanelli L; Petrini I; Gri N; Pasquini G; Rizzo M; Gabelloni M; Belluomini L; Crucitta S; Ciampi R; Frassoldati A; Neri E; Porta C; Danesi R
Cancer Immunol Immunother; 2021 Jun; 70(6):1667-1678. PubMed ID: 33315149
[TBL] [Abstract][Full Text] [Related]
38. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
Zheng B; Ren T; Huang Y; Sun K; Wang S; Bao X; Liu K; Guo W
J Hematol Oncol; 2018 Feb; 11(1):16. PubMed ID: 29409495
[TBL] [Abstract][Full Text] [Related]
39. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.
Koirala P; Roth ME; Gill J; Piperdi S; Chinai JM; Geller DS; Hoang BH; Park A; Fremed MA; Zang X; Gorlick R
Sci Rep; 2016 Jul; 6():30093. PubMed ID: 27456063
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of tumoral PD-L1 expression in Wilms tumors.
Zhang L; Jiao H; Shen M; Liu W; Li Z; Lin J
J Pediatr Urol; 2022 Feb; 18(1):14.e1-14.e8. PubMed ID: 34753665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]